FOR PATIENTS WITH HEMOPHILIA B ACHIEVE
NEW HEIGHTS with proven, long-lasting bleed protection

*Hemophilia FIX Market Assessment. Third-Party Market Research.

†Once well‑controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.

‡The average dose for adults and adolescents receiving prophylaxis every 7 days was 37 IU/kg.

§The median AsBR for people who started on 7- or 14-day prophylaxis was 0. For people who switched to prophylaxis from on-demand, the median AsBR was 0.7. AsBR=annualized spontaneous bleed rate.